Trials / Completed
CompletedNCT02988362
Bioequivalence Study (Candesartan 16 mg and Amlodipine 10 mg)
An Open-label, Randomized, Cross-over Study to Evaluate Pharmacokinetics and the Safety of HL068 16/10mg Compared to Candesartan 16mg and Amlodipine 10mg Co-administered in Healthy Male Volunteers.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- HanAll BioPharma Co., Ltd. · Industry
- Sex
- Male
- Age
- 19 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to compare the safety and pharmacokinetics of HL068 (Candesartan 16 mg and Amlodipine 10mg) with coadministration of the two separate drugs in healthy male volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HL068 16/10mg | Candesartan 16mg and Amlodipine 10mg |
| DRUG | Candesartan 16mg and Amlodipine 10mg |
Timeline
- Start date
- 2016-12-14
- Primary completion
- 2017-02-04
- Completion
- 2017-02-04
- First posted
- 2016-12-09
- Last updated
- 2025-04-04
Source: ClinicalTrials.gov record NCT02988362. Inclusion in this directory is not an endorsement.